NCT00310609已完成3 期
Multicenter, Open-label Study of the Safety (Open-label) and Efficacy (Open-label and Blinded Reader) of a Single Administration of Approximately 0.1 mmol/kg of Magnevist® Injection-enhanced Magnetic Resonance Arteriography (MRA) and 2-dimensional-time-of-flight (2D-TOF) MRA in Patients With Known or Suspected Disease of the Aortic Arch and Cerebral Branches Who Are Undergoing MRA of These Vessels With Intra-arterial Digital Subtraction Arteriography (i.a. DSA) as the Standard of Reference.
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 123
- 主要终点
- Accuracy, sensitivity, and specificity based on quantitative assessment of stenosis assesses by blinded reader
研究概览
简要总结
The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of Magnevist (the study drug) used for MRI of the aortic arch and cerebral branches. The results will be compared to the results of MRI taken without Magnevist, and with the results of your X-ray angiography.
详细描述
This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.Bayer HealthCare Pharmaceuticals, Inc.is the sponsor of the trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Has known or suspected disease of the aortic arch and cerebral branches
- •Is scheduled for X-ray angiography
排除标准
- •Has any contraindication to magnetic resonance imaging
- •Is scheduled for any procedure before the X-ray angiography
- •Had previous bilateral intervention (surgery, bypass) of the arteries of interest
研究组 & 干预措施
Arm 1
Experimental
干预措施: Gadopentetate dimeglumine (Magnevist) (Drug)
结局指标
主要结局
Accuracy, sensitivity, and specificity based on quantitative assessment of stenosis assesses by blinded reader
时间窗: Image creation after injection -evaluation at blind read
次要结局
- Diagnostic confidence(At blinded and/or open label read of the images)
- Visual assessment of stenosis(At blinded and/or open label read of the images)
- Difference in degree of stenosis(At blinded and/or open label read of the images)
- Other diagnostic findings(At blinded and/or open label read of the images)
- Location and matching of stenosis(At blinded and/or open label read of the images)
- Image quality(At blinded and/or open label read of the images)
- Image evaluability and presence of artifacts(At blinded and/or open label read of the images)
- Ability to visualize arterial segments(At blinded and/or open label read of the images)
- Number of evaluable segments(At blinded and/or open label read of the images)
- Duration if 2D TOF and CE-MRA(At blinded and/or open label read of the images)
- Patient management(From baseline to 24 hours follow-up)
- Safety variables(From baseline to 24 hours follow-up)
- Proportion of correctly categorized maximum stenosis per segment(At blinded and/or open label read of the images)
研究者
相似试验
已完成
3 期
Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis in the Calf and/or Pedal ArteriesStenosisNCT00309075Bayer126
已完成
3 期
Magnevist® Injection-enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis of the Renal ArteriesRenal Artery StenosisNCT00310557Bayer116
已完成
3 期
Magnevist® Injection Enhanced MRA at Two Dose Levels Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Infrarenal Aorta and Peripheral ArteriesPeripheral Vascular DiseaseNCT00185276Bayer365
已完成
4 期
Predicting Response to Standardized Pediatric Colitis TherapyUlcerative ColitisNCT01536535Connecticut Children's Medical Center431
已完成
3 期
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)Multiple Sclerosis, Relapsing-RemittingNCT02861014Hoffmann-La Roche681